Recital 15, Regulation (EU) 2016/161

In forcesince 2 Oct 2015cited 3×

The verification of both safety features is necessary to ensure the authenticity of a medicinal product in an end-to end verification system. The verification of the authenticity of the unique identifier aims at ensuring that the medicinal product originates from the legitimate manufacturer. The verification of the integrity of the anti-tampering device shows whether the packaging has been opened or altered since it left the manufacturer, thereby ensuring that the content of the packaging is authentic.

  • Judgment of the Court (Fifth Chamber) of 17 November 2022. Merck Sharp & Dohme BV and Others v Abacus Medicine A/S and Others.Decision

    Recitals 1, 11, 12 and 15 of Delegated Regulation 2016/161 state: Directive [2001/83] provides for measures to prevent the entry into the legal supply chain of falsified medicinal products by requiring the placing of safety features …

    17 Nov 2022 · 62020CJ0224

  • Judgment of the Court (Fifth Chamber) of 17 November 2022. Bayer Intellectual Property GmbH v kohlpharma GmbH.Decision

    Recitals 1, 11, 12 and 15 of Commission Delegated Regulation (EU) 2016/161 of 2 October 2015 supplementing Directive 2001/83 (OJ 2016 L 32, p. 1), state: Directive [2001/83] provides for measures to prevent the entry into the legal supply …

    17 Nov 2022 · 62020CJ0204

  • Judgment of the Court (Fifth Chamber) of 17 November 2022. Novartis Pharma GmbH v Abacus Medicine A/S.Decision

    Recitals 1, 11, 12 and 15 of Delegated Regulation 2016/161 state: Directive [2001/83] provides for measures to prevent the entry into the legal supply chain of falsified medicinal products by requiring the placing of safety features …

    17 Nov 2022 · 62020CJ0147